KATMANDU, 18 February 2021, (TON):  China has announced it decision to provide 500,000 doses of BBIBP-CorV vaccine, developed by Sinopharm, under grant assistance programme.

The Nepalese Department of Drug Administration, The National Drug Regulatory Authority, has granted emergency use approval to a COVID-19 vaccine, “Sinopharm” developed by the Beijing Institute of Biological Products Co Ltd (BIBP) in China. India had also submitted two applications for the approval of its vaccine but it has been rejected.

Emergency Use Authorization (EUA) is granted for some drugs and vaccines by authorities for temporary period during a emergency so that authorities gain time to test and make a judgment to  establish its electiveness, safety and side effects. Such a decision is normally taken when there are evidences to support that patients have recovered from the drug/vaccine.

We cannot ignore to investigate that there is also a general perception that Coronavirus is a biological weapon created to achieve some objectives. Although real, the Coronavirus has been exaggerated manifolds and its spread is intentional against the human rights and other international laws to implement the new strategies of the bankers and businessmen. The package for world governments to introduce smart and strategic technologies based applications and national plans to build future of education, health, economy, services etc. on digital lines, using Artificial Intelligence (AI) and Robotics solutions with focus on operating from home. In the first step old systems, applications, software as well as hardware will be no more compactable and new versions of 5G would be prerequisite to enter into the future. This is aimed to achieve objectives ranging from new businesses to control over the day to day affairs of the whole world.